Estimation of the Number of Respiratory Syncytial Virus-Associated Hospitalizations in Adults in the European Union.

"Potential conflicts of interest. R. O.-Y. reports support from the Innovative Medicines Initiative (IMI)–funded PROMISE consortium. T. K. F. reports support from the IMI-funded PROMISE consortium and consulting fees from Pfizer as chairperson for European Congress of Clinical Microbiology and Infectious Diseases conference symposium on RSV infections among adults. M. B. is an employee of Sanofi Vaccines and may hold stock in the company. H. C. reports grants, personal fees, and nonfinancial support from the World Health Organization, grants and personal fees from Sanofi Pasteur, and grants from the Bill & Melinda Gates Foundation; all payments were made via the University of Edinburgh. H. C. is a shareholder in the Journal of Global Health Ltd. J. P. declares unrestricted grants from Sanofi to the Netherlands Institute for Health Services Research (Nivel) for research on RSV, influenza, and severe acute respiratory syndrome coronavirus 2. Nivel received a research grant from the University of Edinburgh for the submitted work. All other authors report no potential conflicts.: All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed."

"Financial support. This work is part of RESCEU, which has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement 116019). This joint undertaking receives support from the European Union's Horizon 2020 research and innovation program and European Federation of Pharmaceutical Industries and Associations. This publication only reflects the authors’ views, and the joint undertaking is not responsible for any use that may be made of the information it contains herein. Funding to pay the Open Access publication charges for this article was provided by the University of Edinburgh. Financial support."